Squarepoint
ABCL icon

Squarepoint’s AbCellera Biologics ABCL Stock Holding History

Squarepoint’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,749
Closed -$111K – 4327
2026
Q1 		$111K Sell
31,749
-101,320
-76% -$365K ﹤0.01% 4048
2025
Q4 		$455K Buy
133,069
+30,598
+30% +$137K ﹤0.01% 3287
2025
Q3 		$515K Buy
102,471
+88,152
+616% +$388K ﹤0.01% 3207
2025
Q2 		$49.1K Sell
14,319
-4,431
-24% -$11K ﹤0.01% 4308
2025
Q1 		$41.8K Sell
18,750
-38,935
-67% -$112K ﹤0.01% 4371
2024
Q4 		$169K Buy
57,685
+44,367
+333% +$124K ﹤0.01% 4537
2024
Q3 		$34.6K Sell
13,318
-55,590
-81% -$154K ﹤0.01% 3998
2024
Q2 		$204K Buy
68,908
+22,132
+47% +$83.7K ﹤0.01% 3652
2024
Q1 		$212K Sell
46,776
-5,231
-10% -$26.7K ﹤0.01% 3585
2023
Q4 		$297K Buy
52,007
+247
+0.5% +$1.15K ﹤0.01% 3365
2023
Q3 		$238K Sell
51,760
-72,628
-58% -$442K ﹤0.01% 3311
2023
Q2 		$804K Sell
124,388
-34,039
-21% -$232K ﹤0.01% 2328
2023
Q1 		$1.19M Sell
158,427
-39,145
-20% -$355K ﹤0.01% 1775
2022
Q4 		$2M Buy
197,572
+148,779
+305% +$1.72M 0.01% 1364
2022
Q3 		$483K Sell
48,793
-75,570
-61% -$829K ﹤0.01% 2218
2022
Q2 		$1.32M Sell
124,363
-62,446
-33% -$529K 0.01% 1428
2022
Q1 		$1.82M Buy
186,809
+106,528
+133% +$1.01M 0.01% 1209
2021
Q4 		$1.15M Buy
80,281
+23,746
+42% +$360K ﹤0.01% 1608
2021
Q3 		$1.13M Buy
56,535
+33,191
+142% +$587K ﹤0.01% 1500
2021
Q2 		$514K Buy
23,344
+7,683
+49% +$212K ﹤0.01% 2110
2021
Q1 		$532K Buy
+15,661
New +$624K ﹤0.01% 1969

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Squarepoint's ABCL Position: Q2 2026 in Review

Squarepoint sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 31,749 shares — an estimated $111K sold.

Squarepoint first reported a position in ABCL in Q1 2021 and held it in 21 quarters. The position peaked at $2M in Q4 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Squarepoint reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 31,749 AbCellera Biologics shares in Q2 2026, an estimated $111K.
  • Squarepoint first reported a position in AbCellera Biologics in Q1 2021 and held it in 21 quarters.
  • Squarepoint's AbCellera Biologics position peaked at $2M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.